Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029

被引:32
|
作者
Marquina, Clara [1 ]
Talic, Stella [1 ]
Vargas-Torres, Sandra [1 ]
Petrova, Marjana [1 ]
Abushanab, Dina [1 ,2 ]
Owen, Alice [1 ]
Lybrand, Sean [3 ]
Thomson, David [4 ]
Liew, Danny [1 ]
Zomer, Ella [1 ]
Ademi, Zanfina [1 ]
机构
[1] Monash Univ, Sch Publ Hlth & Prevent Med, 553 St Kilda Rd, Melbourne, Vic 3004, Australia
[2] Hamad Med Corp, Dept Pharm, Doha, Qatar
[3] Amgen Europe GmbH, External Access Engagement Value Access & Policy, Zurich, Switzerland
[4] Amgen Australia Pty Ltd, Policy & Advocay, Sydney, NSW, Australia
关键词
Cardiovascular disease; Disease burden; Health economic evaluation; RISK; VALIDATION; STROKE; UTILITIES; MODELS; COST; LIFE;
D O I
10.1093/eurjpc/zwab001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To estimate the health and economic burden of new and established cardiovascular disease from 2020 to 2029 in Australia. Methods and results A two-stage multistate dynamic model was developed to predict the burden of the incident and prevalent cardiovascular disease, for Australians 40-90 years old from 2020 to 2029. The model captured morbidity, mortality, years of life lived, quality-adjusted life years, healthcare costs, and productivity losses. Cardiovascular risk for the primary prevention population was derived using Australian demographic data and the Pooled Cohort Equation. Risk for the secondary prevention population was derived from the REACH registry. Input data for costs and utilities were extracted from published sources. All outcomes were annually discounted by 5%. A number of sensitivity analyses were undertaken to test the robustness of the study. Between 2020 and 2029, the model estimates 377 754 fatal and 991 375 non-fatal cardiovascular events. By 2029, 1 061 756 Australians will have prevalent cardiovascular disease (CVD). The population accrued 8 815 271 [95% uncertainty interval (UI) 8 805 083-8 841 432] years of life lived with CVD and 5 876 975 (5 551 484-6 226 045) QALYs. The total healthcare costs of CVD were projected to exceed Australian dollars (AUD) 61.89 (61.79-88.66) billion, and productivity losses will account for AUD 78.75 (49.40-295.25) billion, driving the total cost to surpass AUD 140.65 (123.13-370.23) billion. Conclusion Cardiovascular disease in Australia has substantial impacts in terms of morbidity, mortality, and lost revenue to the healthcare system and the society. Our modelling provides important information for decision making in relation to the future burden of cardiovascular disease.
引用
收藏
页码:1212 / 1219
页数:8
相关论文
共 50 条
  • [1] Future burden of myocardial infarction in Australia: impact on health outcomes between 2019 and 2038
    Abebe, Tamrat Befekadu
    Morton, Jedidiah, I
    Ilomaki, Jenni
    Ademi, Zanfina
    [J]. EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2023, 10 (05) : 421 - 430
  • [2] Future burden of ischemic stroke in Australia: impact on health outcomes between 2019 and 2038
    Abebe, Tamrat Befekadu
    Morton, Jedidiah I.
    Ilomaki, Jenni
    Ademi, Zanfina
    [J]. NEUROEPIDEMIOLOGY, 2024,
  • [3] Economic Burden of Dementia Caused by Cardiovascular Disease in Australia
    Gao, Lan
    Nguyen, Dieu
    Moodie, Marj
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2022, 86 (02) : 601 - 612
  • [4] Impact of Comorbidities on Economic and Health Outcomes for Patients With Cardiovascular Disease
    Kato, Naoko
    Jaarsma, Tiny
    Kinugawa, Koichiro
    [J]. CIRCULATION JOURNAL, 2014, 78 (03) : 588 - 589
  • [5] PROJECTIONS OF FUTURE HEALTH AND ECONOMIC BURDEN OF CARDIOVASCULAR DISEASE AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS IN AUSTRALIA. ESTIMATES UP TO 2030
    Abushanab, D.
    Liew, D.
    Al-Badriyeh, D.
    Marquina, C.
    Ademi, Z.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S449 - S449
  • [6] Impact and outcomes - The public health burden of insomnia and the economic impact of recent pharmacotherapies
    Kaplan, Gabriel
    [J]. FORMULARY, 2007, : 3 - +
  • [7] Disease burden, associated mortality and economic impact of antimicrobial resistant infections in Australia
    Wozniak, Teresa M.
    Dyda, Amalie
    Merlo, Greg
    Hall, Lisa
    [J]. LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2022, 27 : 1 - 12
  • [8] The Health and Economic Burden of Bushfires in Australia Between 2021 and 2030: A Modelling Study
    Ademi, Z.
    Zomer, E.
    Marquina, C.
    Lee, P.
    Talic, S.
    Guo, Y.
    Liew, D.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S201 - S201
  • [9] THE DISEASE AND ECONOMIC BURDEN OF HEPATOCELLULAR CARCINOMA IN AUSTRALIA
    Gao, L.
    Nguyen, D.
    Mudiyanselage, S. B.
    Tang, B.
    Zhao, F. L.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S181 - S181
  • [10] Identification of Health Expenditures Determinants: A Model to Manage the Economic Burden of Cardiovascular Disease
    Salvatore, Fiorella Pia
    Spada, Alessia
    Fortunato, Francesca
    Vrontis, Demetris
    Fiore, Mariantonietta
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (09)